MD Anderson researchers, led by Renata Ferrarotto, conducted a phase II trial evaluating the combination of the VEGFR inhibitor axitinib plus the PD-L1 inhibitor avelumab in 28 patients with progressive recurrent or metastatic adenoid cystic carcinoma, a rare salivary gland cancer for which there are limited treatment options.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
